Our research focus is clinical computational oncology – the application of computational approaches to leverage the immense available and potential data from tumor genomic profiling to improve outcomes for patients with cancer.
The explosion of tumor genomic data rapidly advanced our understanding of cancer but requires new approaches to answer clinical questions. Specifically, we study resistance to therapy in breast and other cancers by integrating genomic data with patient features and outcomes. By studying patient samples, including on clinical trials, we seek to identify new mechanisms of drug resistance to standard agents as well as investigational agents such as immunotherapy.
The ultimate goal of this work is to identify predictive markers for treatment response while identifying novel susceptibilities that allow us to overcome drug resistance.
Join us in our effort to take terabytes of data and thousands of lines of code back to our true focus – patients with cancer.